DiNardo, C., de Botton, S., Risueño, A., Schuh, A., Löwenberg, B., Kim, H., . . . Hasan, M. (2022). AML-432 Overall survival (OS) by IDH2 mutant allele (R140 or R172) in patients with late-stage, mutant-IDH2 relapsed/refractory acute myeloid leukemia (AML) treated with enasidenib or conventional care regimens (CCR) in the randomized, open-label, Phase 3 IDHENTIFY Trial. Elsevier.
Citação norma ChicagoDiNardo, CD, et al. AML-432 Overall Survival (OS) by IDH2 Mutant Allele (R140 or R172) in Patients with Late-stage, Mutant-IDH2 Relapsed/refractory Acute Myeloid Leukemia (AML) Treated with Enasidenib or Conventional Care Regimens (CCR) in the Randomized, Open-label, Phase 3 IDHENTIFY Trial. Elsevier, 2022.
Citação norma MLADiNardo, CD, et al. AML-432 Overall Survival (OS) by IDH2 Mutant Allele (R140 or R172) in Patients with Late-stage, Mutant-IDH2 Relapsed/refractory Acute Myeloid Leukemia (AML) Treated with Enasidenib or Conventional Care Regimens (CCR) in the Randomized, Open-label, Phase 3 IDHENTIFY Trial. Elsevier, 2022.